Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action (Review)

By Xu Yaping   Sheng Liming   Mao Weimin  

Oncology Letters, Vol. 5, Iss. 1, 2013-01 ,pp. : 19-24

Spandidos Publications

Access to resources Recommend Favorite

Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

By Rae James M.  

Breast Cancer Research and Treatment, Vol. 83, Iss. 2, 2004-01 ,pp. : 99-107

Springer Publishing Company

Access to resources Recommend Favorite

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny

By Suda Kenichi  

Cancer and Metastasis Reviews, Vol. 31, Iss. 3-4, 2012-12 ,pp. : 807-814

Springer Publishing Company

Access to resources Recommend Favorite

Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors

By              

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1794-1800

Spandidos Publications

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite